Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 9;9:730240. doi: 10.3389/fcell.2021.730240

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Lu, Jin, Du, Hu, Wei, Wang, Li and Li.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Clinical outcomes with ICB and lenvatinib. (A) Forest plot analysis of ORR and DCR with ICB combined with lenvatinib across different cancer types. (B) ORR, DCR, and mPFS with pembrolizumab and lenvatinib combined or as monotherapy across different cancer types. 1L, first line therapy; 2L, second line therapy; BLCA, bladder urothelial carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ES, effect size; GBM, glioblastoma multiforme; GC, gastric cancer; HNSC, head and neck squamous cell carcinoma; LIHC, liver hepatocellular carcinoma; mo., month; NSCLC, non-small-cell lung cancer; OV, ovarian serous cystadenocarcinoma; RCC, renal cell carcinoma; READ, rectum adenocarcinoma; SKCM, skin cutaneous melanoma; THCA, thyroid carcinoma; TNBC, triple-negative breast carcinoma; UCEC, uterine corpus endometrial carcinoma.